Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.

BMC Endocr Disord · 2018 · PMC5781307 · PMID 29361932

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

No side effects were reported, except for a quite significant increase in fasting glucose (6.44 mmol/l) and HbA1c (6.5%).

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.